Tag Archive for: Roche

In a neurology update for investors, Roche touted data from a small Ib/IIa trial for trontinemab, an investigational therapy for Alzheimer’s disease which demonstrated “rapid and robust” amyloid plaque reduction.

The companies stated that their experimental drug against high blood pressure was shown to work when used in combination with the standard of care in a phase 2 trial.

Roche on Sunday released results from the first stage of the Phase III OUtMATCH study, demonstrating that its asthma drug Xolair (omalizumab) can significantly reduce severe allergic reactions in patients with several food allergies.

San Francisco-based Rigel Pharmaceuticals on Thursday announced it will acquire the U.S. rights to Blueprint Medicines’ FDA-approved non-small cell lung cancer drug Gavreto (pralsetinib).

Merger and acquisition activity is on the rise after the biopharma industry moved on from the COVID-19 pandemic, while the role of AI in drug development is reaching new levels.

Roivant Sciences announced Tuesday during its third-quarter financial report that it will discontinue the development of its investigational SF3B1 modulator RVT-2001, following an interim analysis of a Phase I/II study in myelodysplastic syndromes.

Roche is returning the global development and commercialization rights to the investigational cancer asset camonsertib to Repare Therapeutics, the Cambridge, Mass. and Montreal-based oncology company announced Monday.

Roche is cutting 345 jobs, Swiss website Muula reported, as the drugs company responds to lower profit posted for 2023 and a more cautious outlook for the year ahead.

The company said its results showed it was overcoming a slump in demand for its COVID-19 products and a decline in sales of a trio of established cancer drugs.

For Sandoz, Monday’s deal with Coherus represents its first major contract since spinning out of Novartis in October 2023.